News Update: Rumour confirmed as Lilly buys Verve Therapeutics Ahead of an opt-in decision on a PCSK9 inhibitor candidate, Eli Lilly is reported to be in advanced takeover negotiations with Verve Therapeutics.
News MSD moves ahead in race to bring oral PCSK9 drug to market Armed with positive results in two phase 3 trials, MSD is poised to be the first to file for approval of an oral PCSK9 drug to lower cholesterol.
News Study links 'bad cholesterol' to dementia Reducing levels of LDL-cholesterol can reduce the risk of dementia by 26%, and statins could add to the benefit, according to a just-published study.
News ACC25: AZ stakes its claim to the oral PCSK9 category AstraZeneca reveals phase 2b results with its oral PCSK9 inhibitor AZD0780 as it tries to narrow a lead held by MSD with its rival cholesterol drug.
Digital A well-kept secret: Applying IEPs to accelerate digital heal... Akira Endo discovered mevastatin, a cholesterol-lowering breakthrough molecule in 1973.
News Novartis builds case for Leqvio with monotherapy data Novartis has a long way to go to make its twice-yearly cholesterol-lowering drug Leqvio the multi-billion-dollar blockbuster it is predicting – but took another step along that road today.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face